Insulin therapy for management of type 2 diabetes mellitus: Strategies for initiation and long-term patient adherence

Journal of the American Osteopathic Association

Volumn 111, Issue 7 SUPPL. 5, 2011, Pages

  Barag, Steven H ^a  

^a Aureus Medical Group Inc and the principal   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; AGED; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSIOLOGY; REVIEW; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051501930     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Diabetes Action Online-About diabetes. World Health Organization Web site. http://www.who.int/diabetesactiononline/diabetes/basics/en/index1.html. Accessed June 14, 2011.
2. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853.
4. Molyneaux LM, Constantino MI, McGill M, Zilkens R, Yue DK. Better glycemic control and risk reduction of diabetic complications in type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract. 1998;42(2):77-83.
5. Hirsch IB, Bergenstal RM, Parkin CG, et al. A realworld approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23(2):78-86.
6. Pearson J, Powers MA. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ. 2006;32(suppl 1):19S-28S.
7. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11): 2673-2679.
8. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-2545.
9. Peyrot M, Rubin RR. Behavioral and psychosocial interventions in diabetes: a conceptual review. Diabetes Care. 2007;30(10):2433-2440.
10. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes [published online ahead of print April 3, 2008]. Int J Clin Pract. 2008;62(6):860-868.
11. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535-1540.
12. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, sub optimal therapy and attitude. QJM. 2000;93 (6):369-374.
13. Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: results of the crossnational Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29(6):1249-1255.
14. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published online ahead of print October 22, 2008]. Diabetologia. 2009;52(1):17-30.
15. Wilson M, Moore MP, Lunt H. Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Res Clin Pract. 2004;66(3):263-267.
16. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care. 2005;28 (1):78-83.
17. Donnelly LA, Morris AD, Evans JM. DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes [published online ahead of print May 15, 2007]. QJM. 2007;100(6): 345-350.
18. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(suppl 1):9S-18S.
19. Meneghini L. "Will I have to be on insulin for the rest of my life?": introduction. Prim Care Diabetes. 2010;4(suppl 1):S1-S2.
20. LaSalle JR. Empowering patients during insulin initiation: a real-world approach. J Am Osteopath Assoc. 2010;110(2):69-78.
21. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial [published online ahead of print March 18, 2008]. Diabetes Obes Metab. 2008;10(5):387-399.
22. Kennedy L, Herman WH, Strange P, Harris A; GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-ofcare versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29(1):1-8.
23. Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin-naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Med Res Opin. 2008;24(1):11-20.
24. Meneghini L, Koenen C, Weng W, Selam JL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes Metab. 2007;9(6):902-913.
25. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes As sociation and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [published correction appears in Circulation. 2009;119(25):e605]. Circulation. 2009;119(2):351-357.
26. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
28. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028-1032.
29. Weng JP, Li YB, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760.
30. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after shortterm intensive insulin therapy [published online ahead of print June 12, 2008]. Diabetes Care. 2008;31(10):1927-1932.
31. Types of insulin-what I need to know about diabetes medicines. National Diabetes Information Clearinghouse Web site. http://diabetes.niddk.nih.gov/dm/pubs/medicines_ez/insert_C.htm. Accessed June 14, 2011.
32. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274.
33. Meneghini L. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract. 2008;62(8):1255-1264.
34. Bretzel RG, Eckhard M, Landgraf W, Owens DR, Linn T. Initiating insulin in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? Diabetes Care. 2009;32(suppl 2):S260-S265.
35. Holman RR, Farmer AJ, Davies MJ, et al. 4-T study group. Three-year efficacy of complex insulin regimens in type 2 diabetes [published online ahead of print October 22, 2009]. N Engl J Med. 2009;361(18):1736-1747.
36. AACE/ACE diabetes algorithm for glycemic control. American Association of Clinical Endocrinologists Web site. https://www.aace.com/sites/default/files/GlycemicControlAlgorithmPPT.pdf. Accessed June 14, 2011.
37. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endo - crinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
38. Karter AJ, Moffet HH, Liu J, et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007;13(11):598-606.
39. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282-1288.
40. Blonde L, Merilainen M, Karwe V, Raskin P. TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab. 2009;11(6):623-631.
41. Oyer DS, Shepherd MD, Coulter FC, et al. INITIATEplus Study Group. A(1c) control in a primary care setting: self-titrating an insulin analog premix (INITIATEplus trial). Am J Med. 2009;122 (11):1043-1049.